No Data
No Data
Yao Yigou (300937.SZ): plans to invest in Xinhuh Chain through capital increase and stock expansion.
HealthTimes 22nd November 丨 To promote cooperation in the pharmaceutical industry, jointly expand the market scale and enhance market influence, the company's wholly-owned subsidiary sichuan PharmaEasy technology Group Co., Ltd. (referred to as "PharmaEasy technology") signed an "Agreement on the Increase of Equity of chongqing Xinhu Medicine Chain Co., Ltd." with chongqing Xinhu Medicine Chain Co., Ltd. (referred to as "Xinhu Chain" or "target company"), chongqing Haihu Group Co., Ltd., Mr. Zhang Yuehong, Ms. Luo Yuqin, and Ms. Zhang Peiyue. PharmaEasy technology plans to invest according to a post-valuation of 0.3 billion yuan, using its own funds of RMB 1,500.
Express News | PharmacyEasy: Wholly-owned subsidiary increased capital to 0.1 billion yuan
A-share SPD concept sector suddenly surged, with multiple stocks hitting the daily limit.
Gelonghui November 12th | Near 10 o'clock in the morning, SPD concept sector suddenly straight up, PharmEasy, Thalys Medical, Hefuchina, Shanghai Kai Kai Industrial, HPGC Renmintongtai Pharmaceutical Corporation, and many other stocks collectively limit up, stimulating retail investors to rise by more than 10%. SPD stands for Supply, Processing, and Distribution, generally known as in-hospital logistics management system, which is an emerging centralized distribution model. It can be generally understood as a management method that centrally and uniformly handles the supply, inventory, and requisition and use of pharmaceuticals and medical devices in these main links.
Express News | The pharmaceutical commerce sector has surged significantly, with many stocks such as Yaoyigou hitting the limit up.
A-share pharmaceutical commerce stocks soared, hpgc renmintongtai hit the limit up.
On November 12, HPGC Renmintongtai Pharmaceutical Corporation hit the limit up, PharmEasy rose more than 10%, Guangxi Liuyao Group, SH Pharma, jointown pharmaceutical group, Shuyu Pingmin and others followed the upward trend.
Medicago: Report for the third quarter of 2024
No Data